As cannabis cultivators pour billions of dollars into developing cutting-edge, efficient grows, we need to ask: is there a hidden disruptor that could steal their business in the years ahead? Here to help us answer this is Kevin Chen of Hyasynth Bio, one of just a few companies experimenting with non-plant-derived cannabinoids. Learn more at https://hyasynthbio.com  Key Takeaways: Kevin’s background in cannabis and how he came to start Hyasynth Bio An inside look at Hyasynth Bio and its work with non-plant-derived cannabinoids A deep dive into biosynthesis and how Hyasynth Bio uses this process to grow cannabis compounds inside yeast cells How Hyasynth Bio has successfully overcome challenges with biosynthesis The history of biosynthesis and cannabis and where Kevin sees this relationship evolving in the years to come  The different types of end products we’ll start to see for sale in dispensaries that use biosynthesis How biosynthesis will affect cannabis prices Hyasynth Bio’s intellectual property strategy and how Kevin manages the company’s patents The traditional cannabis companies that are investing in biosynthesis Where Kevin sees cannabinoid biosynthesis heading in the next 3-5 years